This study will compare, in adults with septic shock, the safety and efficacy of a combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids. In addition, this study will compare the efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone
Objectives: Comparison, in patients with septic shock, of efficacy and safety of the combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids; and of efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone Methods Study design : This is a multicenter, prospective, randomised trial on parallel groups Study treatments : Experimental arm A: A1=50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge. A2=50 mg iv every 6 hours of hydrocortisone (hemisuccinate) for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge. Control arm B: B1:50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days. B2:50 mg iv every 6 hours of hydrocortisone (hemisuccinate)for 7 days. Study Primary outcome : In-hospital mortality Sample size calculation : The expected in-hospital mortality rate in the control group is 50%. To detect an absolute reduction in in-hospital mortality rate of 12.5 %, that is 37.5% in the experimental arm versus 50% in the control arm, and considering risk alpha of 0,05 and a risk beta of 0,20, 254 patients per treatment arms are needed, for a total of 508 patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
508
intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
50 mg as iv bolus every 6 hours for 7 days
50 µg once a day via a nasogastric tube for seven days
Hôpital Avicenne
Bobigny, France
Hôpital Jean Verdier
Bondy, France
CHU Grenoble
Grenoble, France
Hôpital central
Nancy, France
In-hospital mortality
Time frame: Day 180
Secondary outcomes :
Time frame: Day 180
90-day and 180-day mortality.
Time frame: Day 180
Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)
Time frame: Day 180
Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8
Time frame: Day 180
Hospital length of stay.
Time frame: Day 180
Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion
Time frame: Day 180
Muscle weakness at discharge from intensive care unit, 90-day and 180-day
Time frame: Day 180
Post traumatic stress disorders
Time frame: Day 180
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
hydrocortisone 50mg q6 for 7 days
Hôpital Saint Louis
Paris, France
Hôpital Bichat Claude Bernard
Paris, France
hôpital Cochin
Paris, France
Hôpital Delafontaine
Saint-Denis, France